Press Releases

Date	Title	PDF Version
Sep 09, 2020	Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting
Sep 03, 2020	Alexion to Present at Upcoming Virtual Investor Conferences
Aug 06, 2020	Alexion Announces Appointment of First Chief Diversity Officer
Jul 30, 2020	Alexion Reports Second Quarter 2020 Results
Jul 16, 2020	Alexion to Report Second Quarter 2020 Results on Thursday, July 30, 2020
Jul 02, 2020	Alexion Finalizes Settlement with the U.S. Securities and Exchange Commission
Jul 02, 2020	Alexion Completes Acquisition of Portola
Jun 29, 2020	ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)
Jun 24, 2020	Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint
Jun 17, 2020	Alexion Charitable Foundation Announces First Rare Belonging® Grants

Search